Tx delay raises risk in patients with high-risk PCa

San Francisco--A 3-month delay in definitive treatment of high-risk prostate cancer patients seems to increase the risk of recurrence, according to Judd W. Moul, MD, director of the Center for Prostate Disease Research and professor of surgery,